AbbVie (NYSE: ABBV) Beats Q1 2026 EPS Estimates, Raises Full-Year Guidance

AbbVie Inc. (NYSE: ABBV) delivered a stronger-than-expected first quarter, beating EPS estimates and raising its full-year adjusted profit guidance — a combination that underscores the company's ongoing transition beyond Humira. Shares responded modestly, trading at $197.69, up $0.31 (+0.16%) on the day, reflecting a market that had already absorbed some of the recent weakness ahead of the report.

Q1 2026 At a Glance

• Revenue growth (YoY): +10.0%, driven by immunology and neuroscience portfolios
• Gross margin: 71.6%, reflecting strong pricing power across the product mix
• Operating margin: 34.1%, indicating efficient cost management at scale
• Net margin: 6.9%, impacted by GAAP-level items including a reported diluted EPS of $0.39 on a GAAP basis, a year-over-year decrease per the official press release
• Market capitalization: $349.7B at current prices
• Trailing P/E: 83.4x | Forward P/E: 12.3x — a wide gap that signals expected near-term EPS acceleration
• 52-week range: $176.57 – $244.81; current price sits closer to the lower end of that range
• SEC filing: Results of Operations confirmed via 8-K filed April 29, 2026 (Item 9.01)

What Drove the Results

Growth in AbbVie's immunology and neuroscience franchises offset continued pressure from Humira's biosimilar-driven revenue erosion — a dynamic the company has been managing since U.S. exclusivity loss. The strength in these portfolios reflects the commercial ramp of key products that management has positioned as long-term revenue pillars.

The wide divergence between the trailing P/E of 83.4x and forward P/E of 12.3x reflects significant non-cash or one-time charges weighing on current GAAP net income, while analysts project a substantial recovery in adjusted profitability over the next twelve months. The raised full-year guidance reinforces that management sees this trajectory as durable.

Wall Street View

Analyst sentiment around (NYSE: ABBV) remains firmly constructive. As of April 2026, the consensus stands at 7 Strong Buy, 21 Buy, and 11 Hold, with zero Sell or Strong Sell ratings. Compared to the prior month's tally of 7 Strong Buy, 20 Buy, and 12 Hold, there was a modest one-analyst shift from Hold to Buy — a small but directionally positive signal following the earnings beat and guidance raise.

Investor Takeaway

AbbVie's Q1 2026 results demonstrate that its post-Humira diversification strategy is generating real top-line momentum, with 10.0% revenue growth and a raised full-year profit outlook providing tangible evidence of execution. The overwhelmingly constructive analyst consensus — 28 Buy-equivalent ratings against 11 Holds — reflects confidence in the company's pipeline and portfolio depth. With the stock trading near the lower half of its 52-week range, the gap between trailing and forward valuation metrics will be a key focal point for investors assessing re-entry levels.